Teva, Handok to launch joint venture in September

Published: 2013-04-10 06:59:00

Updated: 2013-04-10 06:59:00

A new joint venture between Israel-based Teva Pharmaceutical Industries and Handok Pharmaceutical is expected to commence activities in September, subject to receipt of applicable regulatory approvals after they created the business venture last February.

To this end, the joint venture appoint...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK